Insider · CIK 0001610876

Chodakewitz Jeffrey

CIK 0001610876 Name as filed on the most recent filing

Filed as Chodakewitz Jeffrey (29)

90 transaction lines · from 29 filings · filed 2014-10-09 to 2018-02-14 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.

How this page attributes a trade

A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.

01

Issuers this insider has filed against

Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

No issuer is recorded

The catalog holds no filing linking this CIK to an issuer.

02

Transactions

Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.

90 transactions · Newest transaction date first, id breaking the tie.

Fault

This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-22 05:23 UTC.

Transactions filed by this insider
Direction Date Code Company Value USD Filing
2017-07-21 S, Open-market sale Vertex Pharmaceuticals Inc / MAVRTX 5 lines 1,109,022, disposed Open Form 4 filing 0001209191-17-046026
2017-07-19 S, Open-market sale Vertex Pharmaceuticals Inc / MAVRTX 6,413,113, disposed Open Form 4 filing 0001209191-17-046026
2017-07-17 S, Open-market sale Vertex Pharmaceuticals Inc / MAVRTX 2 lines 74,402, disposed Open Form 4 filing 0001209191-17-045693
2017-07-03 S, Open-market sale Vertex Pharmaceuticals Inc / MAVRTX 2 lines 439,379, disposed Open Form 4 filing 0001209191-17-044104
2017-06-21 S, Open-market sale Vertex Pharmaceuticals Inc / MAVRTX 685,211, disposed Open Form 4 filing 0001209191-17-041635
2017-06-01 S, Open-market sale Vertex Pharmaceuticals Inc / MAVRTX 654,015, disposed Open Form 4 filing 0001209191-17-037925
2017-05-02 S, Open-market sale Vertex Pharmaceuticals Inc / MAVRTX 1,086,908, disposed Open Form 4 filing 0001209191-17-029869
2017-04-05 S, Open-market sale Vertex Pharmaceuticals Inc / MAVRTX 914,394, disposed Open Form 4 filing 0001209191-17-026241
2017-04-03 S, Open-market sale Vertex Pharmaceuticals Inc / MAVRTX 3 lines 249,384, disposed Open Form 4 filing 0001209191-17-025700
2017-03-29 S, Open-market sale Vertex Pharmaceuticals Inc / MAVRTX 1,466,438, disposed Open Form 4 filing 0001209191-17-023840
2017-02-13 S, Open-market sale Vertex Pharmaceuticals Inc / MAVRTX 449,046, disposed Open Form 4 filing 0001209191-17-011107
2017-02-01 S, Open-market sale Vertex Pharmaceuticals Inc / MAVRTX 2 lines 162,897, disposed Open Form 4 filing 0001209191-17-007627
2016-02-02 S, Open-market sale Vertex Pharmaceuticals Inc / MAVRTX 2 lines 217,024, disposed Open Form 4 filing 0001209191-16-095841
2015-11-18 S, Open-market sale Vertex Pharmaceuticals Inc / MAVRTX 1,340,950, disposed Open Form 4 filing 0001209191-15-081528
2015-07-02 S, Open-market sale Vertex Pharmaceuticals Inc / MAVRTX 4 lines 296,357, disposed Open Form 4 filing 0001209191-15-059967
2015-04-02 S, Open-market sale Vertex Pharmaceuticals Inc / MAVRTX 2 lines 264,601, disposed Open Form 4 filing 0001209191-15-032691
2015-02-02 S, Open-market sale Vertex Pharmaceuticals Inc / MAVRTX 3 lines 130,199, disposed Open Form 4 filing 0001209191-15-009464
2015-01-02 S, Open-market sale Vertex Pharmaceuticals Inc / MAVRTX 3 lines 280,735, disposed Open Form 4 filing 0001209191-15-002245
2014-10-28 S, Open-market sale Vertex Pharmaceuticals Inc / MAVRTX 395,370, disposed Open Form 4 filing 0001209191-14-065395
2014-10-07 S, Open-market sale Vertex Pharmaceuticals Inc / MAVRTX 3 lines 358,225, disposed Open Form 4 filing 0001209191-14-062640

This column is intentionally blank

No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.

Codes on this page
S, Open-market sale
Open-market sale
Relationships on this page
O, Officer
Officer

Every value is as reported on the Form 4, totalled to the dollar. Share counts, the price per share and the full list of reporting owners are on each filing's own page, which every row here opens. A row marked n lines adds up that many filed lines of one filing, on one day, on one side of the market; a filing whose lines fall across two pages is left as its lines on both, so no total here is ever short.

What this insider's stored lines contain

Exact counts over every stored line for this entity. This is a statement of composition, not a filter: the only filter this page offers is the open-market one above, because that is the only one an index serves today.

  • Open-market purchase 0
  • Open-market sale 90
  • Option exercise 0
  • Grant or award 0
  • Tax withholding 0
  • Disposition to the issuer 0
  • In-the-money option exercise 0

How to cite this page

ebomi catalog. Chodakewitz Jeffrey, insider transactions. Retrieved 2026-08-25 from https://ebomi.com/insider/0001610876

Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6

This page as JSON The JSON twin is shaped by the same read model as this page, so the two cannot disagree. Its envelope carries the canonical URL, the retrieval time, the coverage claim, and the licence statement.